Hemonetics shares surge over 17% on CSL Plasma supply contract update
HAE Haemonetics Corp
$101.71 -1.75%
View chart & analysis → - 1Hemonetics shares surged more than 17% in pre-market trading on Thursday.
- 2CSL announced it expects to complete the implementation of NexSys PCS devices by 2027, the year it expects to finish adopting CSL's devices and consumables.
- 3Hemonetics will provide an update on the impact of this supply contract on fiscal year 2027 financial results during its second-quarter earnings release in November 2026.
So what's the key point?
Hemonetics shares rose more than 17% following news regarding its equipment supply agreement with CSL Plasma. The company plans to provide an update later on how this contract will affect its fiscal year 2027 financial results.
Source Investing.com +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.